The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 3 (#ACRbest).

The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century.  An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA), the most common form of vasculitis in patients older than 50 years of age.

Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews. Click here to listen.

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews. Click here to listen.

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews. Click here to listen. Content covered includes:

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews. Click here to listen.

Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews. Click here to listen  

At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.  

Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety. 

ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.

Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews. Click here to listen

Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:

Large vessel vasculitis (LVV) and CNS vasculitis are rare subsets of vasculitis. The challenges related to these diseases are well known to the rheumatologists who treat around the world. There are many articles stating that a delay in diagnosis of these diseases leads to increased morbidity and mortality.